JPS6320804B2 - - Google Patents

Info

Publication number: JPS6320804B2
Authority: JP; Japan
Prior art keywords: coenzyme; prostatic hyperplasia; benign prostatic; mitochondria; present
Prior art date: 1978-03-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP3534878A

Other languages

English (en)

Japanese (ja)

Other versions

JPS54129132A (en

Inventor

Tatsuyoshi Murase

Koji Obata

Takamasa Ozawa

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eisai Co Ltd

Original Assignee

Eisai Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-03-29

Filing date

1978-03-29

Publication date

1988-04-30

1978-03-29 Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd

1978-03-29 Priority to JP3534878A priority Critical patent/JPS54129132A/ja

1979-10-06 Publication of JPS54129132A publication Critical patent/JPS54129132A/ja

1988-04-30 Publication of JPS6320804B2 publication Critical patent/JPS6320804B2/ja

Status Granted legal-status Critical Current

Links

ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 36
208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 20
206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 19
235000017471 coenzyme Q10 Nutrition 0.000 claims description 19
238000011282 treatment Methods 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 2
230000003449 preventive effect Effects 0.000 claims 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
239000000203 mixture Substances 0.000 description 12
210000003470 mitochondria Anatomy 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
-1 Nitsukol HCO Chemical class 0.000 description 8
230000000694 effects Effects 0.000 description 8
238000009472 formulation Methods 0.000 description 8
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
229930195725 Mannitol Natural products 0.000 description 7
239000000594 mannitol Substances 0.000 description 7
235000010355 mannitol Nutrition 0.000 description 7
238000000034 method Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
229920000168 Microcrystalline cellulose Polymers 0.000 description 6
239000003814 drug Substances 0.000 description 6
239000008108 microcrystalline cellulose Substances 0.000 description 6
235000019813 microcrystalline cellulose Nutrition 0.000 description 6
229940016286 microcrystalline cellulose Drugs 0.000 description 6
239000000843 powder Substances 0.000 description 6
229920002261 Corn starch Polymers 0.000 description 5
238000007796 conventional method Methods 0.000 description 5
239000008120 corn starch Substances 0.000 description 5
210000002307 prostate Anatomy 0.000 description 5
102000006746 NADH Dehydrogenase Human genes 0.000 description 4
108010086428 NADH Dehydrogenase Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
102000018832 Cytochromes Human genes 0.000 description 3
108010052832 Cytochromes Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
206010036940 Prostatic adenoma Diseases 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
239000005515 coenzyme Substances 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
RBPVKPJDVPPRMI-AVXONLMPSA-N 2-aminoacetic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid Chemical compound NCC(O)=O.C[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O RBPVKPJDVPPRMI-AVXONLMPSA-N 0.000 description 1
230000002407 ATP formation Effects 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
238000009534 blood test Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000004098 cellular respiration Effects 0.000 description 1
239000008695 cernilton Substances 0.000 description 1
230000007665 chronic toxicity Effects 0.000 description 1
231100000160 chronic toxicity Toxicity 0.000 description 1
238000009535 clinical urine test Methods 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000027721 electron transport chain Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
201000004240 prostatic hypertrophy Diseases 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
239000013049 sediment Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229940035936 ubiquinone Drugs 0.000 description 1
210000000626 ureter Anatomy 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1

Landscapes

Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP3534878A 1978-03-29 1978-03-29 Remedy and prophylactic for prostatomegaly Granted JPS54129132A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP3534878A JPS54129132A (en)	1978-03-29	1978-03-29	Remedy and prophylactic for prostatomegaly

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP3534878A JPS54129132A (en)	1978-03-29	1978-03-29	Remedy and prophylactic for prostatomegaly

Publications (2)

Publication Number	Publication Date
JPS54129132A JPS54129132A (en)	1979-10-06
JPS6320804B2 true JPS6320804B2 (ko)	1988-04-30

Family

ID=12439346

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP3534878A Granted JPS54129132A (en)	1978-03-29	1978-03-29	Remedy and prophylactic for prostatomegaly

Country Status (1)

Country	Link
JP (1)	JPS54129132A (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0427901U (ko) *	1990-06-27	1992-03-05
JPH0628644B2 (ja) *	1986-10-17	1994-04-20	ハンス−ヨーアヒム、ウーレマン	心臓診断計器

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5913710A (ja) *	1982-07-15	1984-01-24	Shiseido Co Ltd	養毛料
CN1319534C (zh) *	2004-10-28	2007-06-06	昆明翔昊科技有限公司	含番茄红素和辅酶q10的制剂及其制备方法

1978
- 1978-03-29 JP JP3534878A patent/JPS54129132A/ja active Granted

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0628644B2 (ja) *	1986-10-17	1994-04-20	ハンス−ヨーアヒム、ウーレマン	心臓診断計器
JPH0427901U (ko) *	1990-06-27	1992-03-05

Also Published As

Publication number	Publication date
JPS54129132A (en)	1979-10-06

Publication	Publication Date	Title
RU2468809C2 (ru)	2012-12-10	Экстракт андрографиса метельчатого (andrographis paniculata)
US7182958B1 (en)	2007-02-27	β-carboline pharmaceutical compositions
US5514663A (en)	1996-05-07	Senna dosage form
PL200957B1 (pl)	2009-02-27	Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej
CA2156726C (en)	2000-10-17	Bisacodyl dosage form
US5006551A (en)	1991-04-09	Composition for destroying malignant tumors
JPH09227388A (ja)	1997-09-02	大腸癌、食道癌及び乳癌より選ばれた癌に用いる抗悪性腫瘍剤
HU184219B (en)	1984-07-30	Process for producing pharmaceutical compositions of aggragati on-inhiaiting activity
KR100526278B1 (ko)	2005-11-08	염증성 장질환의 예방 또는 치료제
Barton et al.	1986	Bone metastases in malignant gastrinoma
JP2018508479A (ja)	2018-03-29	虚血性脳卒中を予防・治療するための薬物の調製におけるビフェノールの使用
KR20180035739A (ko)	2018-04-06	조직 재생 및 저하된 조직 기능의 회복을 자극하기 위한 제제로서의 디카르복시산의 비스아미드 유도체
JPH0133082B2 (ko)	1989-07-11
JPS6320804B2 (ko)	1988-04-30
EP0059148B1 (fr)	1985-05-29	Le chlorure de gallium, nouveau médicament anti-cancéreux
AU2017259749A1 (en)	2018-12-20	Phenol compound and combination of same with a benzodiazepine fused to 1,4-dihydropyridine for treating diseases of the central nervous and vascular systems
Premalatha et al.	2000	Stabilization of lysosomal membrane and cell membrane glycoprotein profile by Semecarpus anacardium Linn. nut milk extract in experimental hepatocellular carcinoma
Delmont et al.	1975	Prostaglandins and carcinoid tumours.
KR20000022204A (ko)	2000-04-25	구내염의 치료 및 예방제
JPH0132804B2 (ko)	1989-07-10
JP3587247B2 (ja)	2004-11-10	炎症性腸疾患の予防・治療剤
US4882314A (en)	1989-11-21	A composition and method of treating selected malignant conditions
JPS60155125A (ja)	1985-08-15	フエニルケトン尿症用剤
JPH02215724A (ja)	1990-08-28	ミミズ乾燥粉末の製造法
JPH02215725A (ja)	1990-08-28	抗高脂血症剤

JPS6320804B2 - - Google Patents

Info

Links

Landscapes

Priority Applications (1)

Applications Claiming Priority (1)

Publications (2)

Family

ID=12439346

Family Applications (1)

Country Status (1)

Cited By (2)

Families Citing this family (2)

Cited By (2)

Also Published As

Similar Documents